2-(4-Chlorophenylsulfonylamino)-N-(2-naphthyl)benzamide | 254432-20-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(4-Chlorophenylsulfonylamino)-N-(2-naphthyl)benzamide
• 英文别名: 2-[(4-chlorophenyl)sulfonylamino]-N-naphthalen-2-ylbenzamide
• CAS: 254432-20-7
• 化学式: C₂₃H₁₇ClN₂O₃S
• 分子量: 436.919
• InChiKey: FIKKRYWNNGBXHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• SULFONYLAMINO-CARBONSÄURE-N-ARYLAMIDE ALS GUANYLATCYCLASE-AKTIVATOREN
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1095015B1

  公开（公告）日：2005-06-01
• Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20030171352A1

  公开（公告）日：2003-09-11

  The present invention relates to compounds of the formula I 1 in which A 1 , A 2 , R 2 and R 3 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention relates to the use of compounds of the formula I for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, novel compounds of the formula I, pharmaceutical preparations comprising them and processes for their preparation.
• US6548547B1
  申请人：——

  公开号：US6548547B1

  公开（公告）日：2003-04-15
• US6809089B2
  申请人：——

  公开号：US6809089B2

  公开（公告）日：2004-10-26
• US7351703B2
  申请人：——

  公开号：US7351703B2

  公开（公告）日：2008-04-01